In a new study published in the journal Brain Research,
lab rodents with age- and Alzheimer’s-related brain deterioration were
given a triple receptor drug that protects brain cells in three ways.
The animals were then put through a maze to test their memory.

Mice given the drug showed memory improvement and reduced plaque
buildup in the brain, a telltale sign of Alzheimer’s. The mice also
showed improvement in terms of inflammation and cellular health of the
brain.
Findings suggest that the drug “holds clear promise of being developed
into a new treatment for chronic neurodegenerative disorders such as
Alzheimer’s disease,” said senior author Christian Hölscher of Lancaster
University in the UK.
Alzheimer’s experts said that the results are especially encouraging
since there have been “no new (Alzheimer’s) treatments in nearly 15
years.”
The drug, referred to as a “triple receptor agonist” by researcher,
acts in a number of ways to protect the brain from degeneration by
simultaneously activating the trio of growth factors GIP-1, GIP and
glucagon. Growth factors are proteins that stimulate the growth of specific tissues.
The connection between diabetes and Alzheimer’s disease has been studied for several years. The new development and potential treatment option is exciting since more than 5 million Americans are now living with Alzheimer’s. By 2050 that number could be as high as 16 million.
No comments:
Post a Comment